Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Cyclerion Therapeutics (CYCN) over the last 5 years, with Q3 2025 value amounting to $1.8 million.

  • Cyclerion Therapeutics' Cash from Financing Activities changed N/A to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2023, which is 1722413.79% up from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Cash from Financing Activities of $1.8 million as of Q3 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Cash from Financing Activities peaked at $30.6 million during Q2 2021, and registered a low of -$130000.0 during Q2 2025.
  • For the 3-year period, Cyclerion Therapeutics' Cash from Financing Activities averaged around $3.8 million, with its median value being $43000.0 (2021).
  • In the last 5 years, Cyclerion Therapeutics' Cash from Financing Activities soared by 260000.0% in 2021 and then tumbled by 9994.45% in 2022.
  • Cyclerion Therapeutics' Cash from Financing Activities (Quarter) stood at $85000.0 in 2021, then tumbled by 85.88% to $12000.0 in 2022, then soared by 15116.67% to $1.8 million in 2025.
  • Its Cash from Financing Activities was $1.8 million in Q3 2025, compared to -$130000.0 in Q2 2025 and $1.4 million in Q1 2025.